Literature DB >> 24940638

miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production.

Sinéad Weldon1, Paul McNally, Danny F McAuley, Irene K Oglesby, Christine L Wohlford-Lenane, Jennifer A Bartlett, Christopher J Scott, Noel G McElvaney, Catherine M Greene, Paul B McCray, Clifford C Taggart.   

Abstract

RATIONALE: Cathepsin S (CTSS) activity is increased in bronchoalveolar lavage (BAL) fluid from patients with cystic fibrosis (CF). This activity contributes to lung inflammation via degradation of antimicrobial proteins, such as lactoferrin and members of the β-defensin family.
OBJECTIVES: In this study, we investigated the hypothesis that airway epithelial cells are a source of CTSS, and mechanisms underlying CTSS expression in the CF lung.
METHODS: Protease activity was determined using fluorogenic activity assays. Protein and mRNA expression were analyzed by ELISA, Western blotting, and reverse-transcriptase polymerase chain reaction.
MEASUREMENTS AND MAIN RESULTS: In contrast to neutrophil elastase, CTSS activity was detectable in 100% of CF BAL fluid samples from patients without Pseudomonas aeruginosa infection. In this study, we identified epithelial cells as a source of pulmonary CTSS activity with the demonstration that CF airway epithelial cells express and secrete significantly more CTSS than non-CF control cells in the absence of proinflammatory stimulation. Furthermore, levels of the transcription factor IRF-1 correlated with increased levels of its target gene CTSS. We discovered that miR-31, which is decreased in the CF airways, regulates IRF-1 in CF epithelial cells. Treating CF bronchial epithelial cells with a miR-31 mimic decreased IRF-1 protein levels with concomitant knockdown of CTSS expression and secretion.
CONCLUSIONS: The miR-31/IRF-1/CTSS pathway may play a functional role in the pathogenesis of CF lung disease and may open up new avenues for exploration in the search for an effective therapeutic target.

Entities:  

Keywords:  cystic fibrosis; epithelium; microRNA; protease

Mesh:

Substances:

Year:  2014        PMID: 24940638      PMCID: PMC4226050          DOI: 10.1164/rccm.201311-1986OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  51 in total

Review 1.  IRF family of transcription factors as regulators of host defense.

Authors:  T Taniguchi; K Ogasawara; A Takaoka; N Tanaka
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Identification of novel genes coding for small expressed RNAs.

Authors:  M Lagos-Quintana; R Rauhut; W Lendeckel; T Tuschl
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

3.  An in vitro model of differentiated human airway epithelia. Methods for establishing primary cultures.

Authors:  Philip H Karp; Thomas O Moninger; S Pary Weber; Tamara S Nesselhauf; Janice L Launspach; Joseph Zabner; Michael J Welsh
Journal:  Methods Mol Biol       Date:  2002

4.  Accessory cell function of airway epithelial cells.

Authors:  Erwin Oei; Thomas Kalb; Prarthana Beuria; Matthieu Allez; Atsushi Nakazawa; Miyuki Azuma; Michael Timony; Zanetta Stuart; Houchu Chen; Kirk Sperber
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-08       Impact factor: 5.464

5.  Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease.

Authors:  Mark O Wielpütz; Michael Puderbach; Annette Kopp-Schneider; Mirjam Stahl; Eva Fritzsching; Olaf Sommerburg; Sebastian Ley; Migle Sumkauskaite; Jürgen Biederer; Hans-Ulrich Kauczor; Monika Eichinger; Marcus A Mall
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

6.  IFN regulatory factor-1 regulates IFN-gamma-dependent cathepsin S expression.

Authors:  Karin Storm van's Gravesande; Matthew D Layne; Qiang Ye; Louis Le; Rebecca M Baron; Mark A Perrella; Laura Santambrogio; Eric S Silverman; Richard J Riese
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

7.  Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins.

Authors:  Clifford C Taggart; Catherine M Greene; Stephen G Smith; Rodney L Levine; Paul B McCray; Shane O'Neill; Noel G McElvaney
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

8.  Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis.

Authors:  Mark P Rogan; Clifford C Taggart; Catherine M Greene; Philip G Murphy; Shane J O'Neill; Noel G McElvaney
Journal:  J Infect Dis       Date:  2004-08-26       Impact factor: 5.226

9.  Characterization of human tracheal epithelial cells transformed by an origin-defective simian virus 40.

Authors:  D C Gruenert; C B Basbaum; M J Welsh; M Li; W E Finkbeiner; J A Nadel
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

10.  Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis.

Authors:  J Kos; A Sekirnik; G Kopitar; N Cimerman; K Kayser; A Stremmer; W Fiehn; B Werle
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

View more
  19 in total

Review 1.  Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges.

Authors:  Klaudia Brix; Joseph McInnes; Alaa Al-Hashimi; Maren Rehders; Tripti Tamhane; Mads H Haugen
Journal:  Protoplasma       Date:  2014-11-16       Impact factor: 3.356

2.  Kinetics of microRNA Expression in Bronchoalveolar Lavage Fluid Samples.

Authors:  Matthias Brock; Thomas Rechsteiner; Malcolm Kohler; Daniel Franzen; Lars C Huber
Journal:  Lung       Date:  2015-03-21       Impact factor: 2.584

Review 3.  ncRNA-regulated immune response and its role in inflammatory lung diseases.

Authors:  Na Xie; Gang Liu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-02       Impact factor: 5.464

Review 4.  Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential.

Authors:  Michael C McKelvey; Sinéad Weldon; Daniel F McAuley; Marcus A Mall; Clifford C Taggart
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

5.  Design of a highly selective quenched activity-based probe and its application in dual color imaging studies of cathepsin S activity localization.

Authors:  Kristina Oresic Bender; Leslie Ofori; Wouter A van der Linden; Elliot D Mock; Gopal K Datta; Somenath Chowdhury; Hao Li; Ehud Segal; Mateo Sanchez Lopez; Jonathan A Ellman; Carl G Figdor; Matthew Bogyo; Martijn Verdoes
Journal:  J Am Chem Soc       Date:  2015-04-01       Impact factor: 15.419

Review 6.  Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn's Disease: The Path From Bench to Bedside.

Authors:  Long-Yuan Zhou; Si-Nan Lin; Florian Rieder; Min-Hu Chen; Sheng-Hong Zhang; Ren Mao
Journal:  Inflamm Bowel Dis       Date:  2021-06-15       Impact factor: 7.290

7.  Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation.

Authors:  Ping-Xia Zhang; Jijun Cheng; Siying Zou; Anthony D D'Souza; Jonathan L Koff; Jun Lu; Patty J Lee; Diane S Krause; Marie E Egan; Emanuela M Bruscia
Journal:  Nat Commun       Date:  2015-02-10       Impact factor: 14.919

Review 8.  MicroRNA Dysregulation in Cystic Fibrosis.

Authors:  Paul J McKiernan; Catherine M Greene
Journal:  Mediators Inflamm       Date:  2015-06-22       Impact factor: 4.711

Review 9.  Non-Coding RNAs in Pediatric Airway Diseases.

Authors:  Beata Narożna; Wojciech Langwiński; Aleksandra Szczepankiewicz
Journal:  Genes (Basel)       Date:  2017-11-27       Impact factor: 4.096

10.  Protein Phosphatase 2A Reduces Cigarette Smoke-induced Cathepsin S and Loss of Lung Function.

Authors:  Declan F Doherty; Sridesh Nath; Justin Poon; Robert F Foronjy; Michael Ohlmeyer; Abdoulaye J Dabo; Matthias Salathe; Mark Birrell; Maria Belvisi; Nathalie Baumlin; Michael D Kim; Sinéad Weldon; Clifford Taggart; Patrick Geraghty
Journal:  Am J Respir Crit Care Med       Date:  2019-07-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.